Efficacy and Safety of 4 Doses of QGE031 in Patients 18-50 Years of Age With Peanut Allergy
Peanut AllergyThis study will assess the clinical potency of several exposure levels of QGE031 in decreasing the sensitivity against peanut allergen.
Walnut Oral Immunotherapy for Tree Nut Allergy
Peanut AllergyThe purpose of this research study is to learn about the medical effects, safety, and how the Walnut Oral Immunotherapy (OIT) treatment affects your body (immune system). This type of immunotherapy involves giving increasing doses of walnut allergen to gradually build up a person's tolerance to walnut and at least one other tree nut. The goal of the study is to determine whether participants can tolerate (eat) walnuts and at least one other tree nut in their diet after stopping the study therapy.
Novel Treatment for Patients With Peanut Allergy: Intralymphatic Immunotherapy
Food Allergy PeanutUse of three intralymphatic injections of peanut allergen one month apart to induce tolerance to peanut in peanut allergic people.
Tolerance Following Peanut Oral Immunotherapy
Peanut AllergyThe unifying objective of this project is to determine whether peanut oral immunotherapy (PN OIT) induced clinical tolerance in the context of food allergy is significantly associated with the expansion of a specific regulatory T cell subset (CD45RA- CD25++ FoxP3++) that is thought to be inducible in the gut-associated lymphoid compartment and associated with immunological tolerance. The hypothesis of the study is that the induction of Treg cells will be associated with clinical tolerance. The investigators will measure the change from baseline of induced Treg cells as a frequency of total CD4 T cells during active treatment and compare that between participants who achieve significant clinical tolerance (Tolerance and Partial Tolerance Groups as defined below) and those who do not (Treatment Failure Group).
A Study to Assess the Biological Potency of Peanut Allergen Extract in Adolescent and Adult Peanut...
Peanut AllergyThe study aims to assess the biological potency of the In-House Reference Preparation (IHRP) of peanut allergens extract by a quantitative Skin Prick Test (SPT) method in peanut-allergic subjects.
Allergy Experience Study
Peanut AllergyPeople who are undergoing oral immunotherapy for food allergy treatment can feel anxious about the treatment process, particularly when they have allergic responses (e.g., hives, vomiting, nausea) during the dosing process. People may commonly believe that these symptoms are simply side effects that must be endured or avoided. However, the investigators propose that changing participants' mindsets about the meaning of symptoms-toward viewing them as a sign that the treatment is working and desensitization is increasing-during the treatment process will reduce anxiety and improve treatment outcomes.
The Grown Up Peanut Immunotherapy Study
Peanut AllergyTo determine efficacy and safety of peanut oral immunotherapy in adults with peanut allergy.
Treatment of Severe Peanut Allergy With Xolair (Omalizumab) and Oral Immunotherapy
Peanut AllergySevere peanut allergy is different from other allergic reactions because it can lead to fatal reactions and is an invisible disability. There is no cure today. The purpose of this study is to treat children and adolescents with severe peanut allergy with oral immunotherapy with peanuts under the protection of anti-IgE (immunoglobulin E) antibodies (omalizumab), and thereby inducing tolerance to peanuts. The treatment will be monitored by basophil cell stimulation (CD-sens).
Pilot Study to Evaluate the Effect of Ketotifen on the Adverse Events Associated With Peanut Desensitization...
Peanut Allergies in ChildrenThe primary objective of this study is to evaluate, compared to non-treatment, the impact of a titrated dose (1 mg once a day, then 1 mg twice a day and finally a full 2 mg twice a day) of ketotifen on the adverse event profile emerging from a rapid peanut desensitization protocol, in children with established peanut allergy.
High and Low Dose Oral Peanut Immunotherapy - Comparison of Efficacy and Safety
Peanut AllergyIn this trial the investigators aim to assess the effectiveness and safety of oral immunotherapy with peanut protein in high and low dose (300mg versus 150mg) in children with peanuts allergy.